Subscribe To
AQST / Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
AQST News
By Zacks Investment Research
November 1, 2023
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close. more_horizontal
By Zacks Investment Research
October 9, 2023
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day. more_horizontal
By Seeking Alpha
September 22, 2023
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both
Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture sign more_horizontal
By Zacks Investment Research
September 13, 2023
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know
Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day. more_horizontal
By Zacks Investment Research
September 12, 2023
Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up
Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure more_horizontal
By Zacks Investment Research
August 7, 2023
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares more_horizontal
By Zacks Investment Research
July 26, 2023
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues. more_horizontal
By Seeking Alpha
July 25, 2023
Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem
Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/ more_horizontal